FDAsafety guidance77% confidence
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as Macleods Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Cardiology · Mineralocorticoid Receptor Antagonist
- Sub-indication
- Hypertension
Related signal: FDA Submission for Finerenone by Macleods Pharmaceuticals